The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1379
Safety of Dronedarone (Multaq)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Dronedarone (Multaq – Sanofi), an analog of amiodarone, was approved by the FDA in 2009 for oral treatment of paroxysmal or persistent (non-permanent) atrial fibrillation or atrial flutter.1 Amiodarone (Cordarone, and others) is more effective for this indication,2 but its use is often limited by its adverse effects, including thyroid and pulmonary toxicity.

ADVERSE EFFECTS OF DRONEDARONE — Diarrhea, nausea, vomiting, abdominal pain and rash can occur with dronedarone, but unlike amiodarone, significant thyroid or ocular toxicity has not been reported to date. Photosensitivity has been reported, but not the blue-gray skin discoloration associated with amiodarone. Both amiodarone and dronedarone have the potential to interact with many other drugs taken concomitantly.

After an earlier trial was terminated prematurely ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Safety of Dronedarone (Multaq)
Article code: 1379f
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian